| S7540 |
SB273005
|
SB273005 is a potent integrin inhibitor with Ki of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.
|
-
EMBO J, 2025, 10.1038/s44318-025-00565-3
-
bioRxiv, 2025, 2025.04.25.650475
-
Cancer Lett, 2024, 582:216597
|
|
| S7077 |
Cilengitide trifluoroacetate
|
Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.
|
-
J Neuroinflammation, 2025, 22(1):168
-
Int J Mol Sci, 2025, 26(6)2465
-
Microbiol Spectr, 2025, 13(2):e0222124
|
|
| S6387 |
Cilengitide (EMD 121974)
|
Cilengitide (EMD 121974, EMD-12192, EMD-85189, NSC-707544) is a potent and selective inhibitor of the integrins ανβ3 and ανβ5 with IC50 of 4 and 79 nM, respectively.
|
-
Nat Commun, 2025, 16(1):2254
-
NPJ Regen Med, 2024, 9(1):4
-
World J Gastroenterol, 2024, 30(7):728-741
|
|
| S8008 |
RGD peptide (Arg-Gly-Asp)
|
RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.
|
-
Adv Sci (Weinh), 2025, 12(18):e2417447
-
J Sport Health Sci, 2024, S2095-2546(24)00124-8
-
iScience, 2024, 27(3):109119
|
|
| S8454 |
ATN-161
|
ATN-161 is a novel small peptide antagonist of integrin α5β1. It binds to several integrins, including α5β1 and αvβ3, that play a role in angiogenesis and tumor progression.
|
-
Nat Commun, 2025, 16(1):6531
-
Nat Commun, 2025, 16(1):9183
-
Regen Biomater, 2025, 12:rbaf099
|
|
| S7844 |
Cyclo(RGDyK) TFA
|
Cyclo(RGDyK) TFA is a salt formed by the combination of Cyclo(RGDyK) and trifluoroacetate (TFA). It is an effective and selective Integrin αvβ3 inhibitor with a low IC50 value (e.g., 20 nM). This compound is of great significance in the treatment of cardiovascular diseases, osteoporosis, inflammation and tumors.
|
-
J Clin Invest, 2024, e175147
-
JBMR Plus, 2024, ziae066
-
JBMR Plus, 2024, 8(7):ziae066
|
|
| S7834 |
Cyclo(-RGDfK) TFA
|
Cyclo(-RGDfK) TFA is the salt product of Cyclo(-RGDfK) and trifluoroacetic acid (TFA). The addition of TFA enhances stability and biocompatibility. This compound effectively targets tumor microvessels and cancer cells by specifically binding to the cell surface Integrin αvβ3.
|
-
International Immunopharmacology, January 15, 2026, 115975
-
Pharmaceuticals (Basel), 2025, 18(4)549
-
In Vitro Cell Dev Biol Anim, 2025, 10.1007/s11626-025-01101-7
|
|
| S2885 |
A-205804
|
A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively.
|
-
Cell Biol Toxicol, 2024, 40(1):90
-
Advanced Healthcare Materials, 2023, e2301673
-
Stem Cell Res Ther, 2022, 13(1):218
|
|
| S8306 |
Leukadherin-1
|
Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1 (an agonist for the complement receptor 3 (CD11b/CD18)).
|
-
Ecotoxicology and Environmental Safety, 2023, 115550
-
International Immunopharmacology, 2023, Volume 118
-
Int Immunopharmacol, 2023, 118:110024
|
|
| S4513 |
RGD peptide (GRGDNP)
|
RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. This compound induces apoptosis presumably through direct activation of caspase-3.
|
-
Pharmacological Research, 2024, 107269
-
npj Precision Oncology, 2024, 127
-
Traditional Medicine Research, 2023, 50
|
|